Table 1.

Clinicopathological characteristics of patients with recurrence and recurrence-free

Characteristic	Total		Recurrence-free		Recurrence		P-value
	n=182	100%	n=94	100%	n=88	100%
Sex							0.706
Male	106	58.2%	56	59.6%	50	56.8%
Female	76	41.8%	38	40.4%	38	43.2%
Age							0.269
≤48	46	25.3%	27	28.7%	19	21.6%
>48	136	74.7%	67	71.3%	69	78.4%
Jaundice							0.316
No	41	22.5%	24	25.5%	17	19.3%
Yes	141	77.5%	70	74.5%	71	80.7%
Intraoperative transfusion							0.116
No	70	38.5%	31	33.0%	39	44.3%
Yes	112	61.5%	63	67.0%	49	55.7%
Operation time							0.673
≤6 hours	139	76.4%	73	77.7%	66	75.0%
>6 hours	43	23.6%	21	22.3%	22	25.0%
Tumor size							0.301
≤2.2 cm	92	50.5%	51	54.3%	41	46.6%
>2.2 cm	90	49.5%	43	45.7%	47	53.4%
Differentiation							0.013
Poor	54	29.7%	21	22.3%	33	37.5%
Moderate	81	44.5%	41	43.6%	40	45.5%
Well	47	25.8%	32	34.0%	15	17.0%
Regional nodes examined							0.085
≤11	113	62.1%	64	68.1%	49	55.7%
>12	69	37.9%	30	31.9%	39	44.3%
T stage							0.007
T1	25	13.7%	18	19.1%	7	8.0%
T2	72	39.6%	42	44.7%	30	34.1%
T3	85	46.7%	34	36.2%	51	58.0%
N stage							0.011
N0	134	73.6%	78	83.0%	56	63.6%
N1	40	22.0%	14	14.9%	26	29.5%
N2	8	4.4%	2	2.1%	6	6.8%
TNM stage							0.001
l	81	44.5%	54	57.4%	27	30.7%
ll	53	29.1%	24	25.5%	29	33.0%
lll	48	26.4%	16	17.0%	32	36.4%
Lymphovascular invasion							<0.001
No	156	85.7%	90	95.7%	66	75.0%
Yes	26	14.3%	4	4.3%	22	25.0%
Postoperative complications							0.377
No	114	62.6%	56	59.6%	58	65.9%
Yes	68	37.4%	38	40.4%	30	34.1%
Adjuvant treatment							<0.001
No	143	78.6%	84	89.4%	59	67.0%
Yes	39	21.4%	10	10.6%	29	33.0%